• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Inhibikase Therapeutics receives Orphan Drug Designation for PML

Inhibikase Therapeutics receives Orphan Drug Designation for PML

May 22, 2014
CenterWatch Staff

Inhibikase Therapeutics, a developer of products to treat infectious diseases with little or no resistance, has received Orphan Drug Designation for imatinib to treat progressive multifocal leukoencephalopathy (PML) from the FDA.

PML is a rare side effect of small molecule and antibody drugs given to patients with autoimmune diseases like arthritis and multiple sclerosis (MS); PML also occurs in 1%-3% of clinical AIDS patients. Certain drugs used to treat autoimmune disease suppress the ability of a patient to fight infection, particularly for the virus known as JC (for John Cunningham virus). JC lives inside most people, but when the immune system is suppressed, JC can occasionally migrate into the brain, “blowing up” certain brain cells that results in a debilitating loss of cognitive and motor neuron function, often culminating in a patient's death.

"MS can be a very disabling disease. To date, Tysabri is our most effective treatment," said neurologist Dr. Jeffrey B. English, director of Clinical Research at the MS Center of Atlanta.  "Unfortunately, it carries a risk of a life threatening brain infection that can lead to PML. There are ways to screen for PML early, but we have no effective treatments for this disease."

Imatinib, the active ingredient in the company's lead product IkT-001Pro, is a host-directed protein kinase inhibitor that disrupts the ability of JC virus to reproduce in the patient.  IkT-001Pro delivers imatinib to its targets using a proprietary technology that should reduce the dose and side effects of imatinib therapy while simultaneously enhancing imatinib's ability to suppress the causative virus of PML. Imatinib also is the active ingredient in the anti-cancer drug Gleevec, developed by Novartis and used to treat certain forms of blood and stomach cancer.

"The anti-JC virus activity of imatinib cannot be achieved by simply altering the frequency or amount of Gleevec given to patients," said Milton H. Werner, Ph.D., president and CEO of Inhibikase.  "Early trial work has already shown this. To succeed, we're talking reengineering how imatinib is absorbed and distributed in the body."

"The granting of Orphan Drug Designation is a pivotal milestone in the development of IkT-001Pro to treat this rare and debilitating illness," said Werner. "The designation will enable resources for continued development, but more importantly the designation provides an additional avenue for discussion with the FDA on the best path for bringing IkT-001Pro to market. PML is a rare side effect of at least 13 beneficial medications, and PML also may arise as a side effect of many more medications now in clinical development. IkT-001Pro, when administered as a companion therapeutic, could reduce the risks of these marketed and investigational treatments, thereby improving patient safety and focusing treatment decisions on the efficacy of the treatment, not just on the risk of an unintended and potentially fatal side effect."

"PML can pose a grave risk to people with MS and other disorders who use powerful immune-modulating therapies, and this risk often forces people to avoid or limit the use of otherwise very effective treatments," said Dr. Timothy Coetzee, chief advocacy, services and research officer at the National MS Society. "This Orphan Drug Designation by the FDA should provide incentive to develop a program focusing on the unmet need of a treatment for PML."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing